Loading...

MHN Darbepoetin Alfa Coverage Update | OpenPayer

ModifiedmhnPolicy CP.PHAR.236

Darbepoetin Alfa (Aranesp) coverage

Defines medical necessity criteria, prior authorization and continuation requirements for darbepoetin alfa (Aranesp) for anemia from CKD, chemotherapy-associated anemia, myelodysplastic syndrome, myelofibrosis, and other indications for members of the payer's lines of business.

Policy Summary

Payermhn

PolicyDarbepoetin Alfa (Aranesp) coverage

Policy CodePolicy CP.PHAR.236

Change TypeMaterial updates to step therapy/redirection, IL HIM bypass added, MDS continuation timing, CKD approval duration extended

Effective DateJul 1, 2016

Next Review Date

Key ActionPrior authorization required; provider must document diagnosis, specialist involvement, iron studies, pretreatment hemoglobin and adherence to step therapy/redirection logic or applicable state exemptions.

SourceLink

POLICY UPDATE CHANGES

For all indications, revised Retacrit and Epogen redirection language from 'failure of' to 'member must use' and revised criteria from 'member meets one of the following' to 'member must meet both of the following', clarified members must use Epogen if member is unable to use Retacrit.

Added step therapy bypass for Illinois HIM requests per IL HB 5395 (effective 1/1/2026) that removes step therapy requirements for those requests.

For anemia associated with MDS, continuation of therapy response assessment modified to occur after at least 8 weeks of therapy (previously 12 weeks) and added approval pathway for lower risk (IPSS low/intermediate-1) disease with del(5q).

Extended continuation of therapy approval duration from 6 to 12 months for Medicaid/HIM for anemia due to CKD.

Added step therapy bypass for IL HIM per IL HB 5395.

≥100Iron stores threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Darbepoetin alfa (Aranesp)

Anemia due to Chronic Kidney Disease — Initial Therapy

Covered when ALL of the following are met:

CKD initial: 1. Diagnosis of anemia of chronic kidney disease (dialysis and non-dialysis). 2. Prescribed by or in consultation with a hematologist or nephrologist. 3. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or transferrin saturation (TSAT) ≥ 20%. 4. Pretreatment hemoglobin < 10 g/dL. 5. Member meets both of the following: (a) Member must use Retacrit unless contraindicated, clinically significant adverse effects occur, or Retacrit is unavailable due to shortage; (b) If unable to use Retacrit, member must use Epogen unless contraindicated or clinically significant adverse effects occur. Note: For Illinois Humana Integrated Medicaid (IL HIM) requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. Prior authorization may be required for Retacrit or Epogen.

Anemia due to Chemotherapy in Patients with Cancer — Initial Therapy

Covered when ALL of the following are met:

Chemo-associated initial: 1. Indication: solid or non-myeloid malignancy. 2. Member is receiving myelosuppressive chemotherapy without curative intent. 3. Prescribed by or in consultation with a hematologist or oncologist. 4. Age ≥ 18 years. 5. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or TSAT ≥ 20%. 6. Pretreatment hemoglobin < 10 g/dL. 7. Member meets step therapy: either (a) both (i) member must use Retacrit unless contraindicated/AE/shortage and (ii) if unable to use Retacrit, member must use Epogen unless contraindicated; or (b) request is for treatment in a state with regulations against step therapy in certain oncology settings (see Appendix D). Note: For IL HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. Prior authorization may be required for Retacrit or Epogen. Additional operational note: must have at least 2 additional months of planned chemotherapy per FDA labeling where applicable.

Myelodysplastic Syndrome (MDS) — Initial Therapy (off-label)

Covered when ALL of the following are met:

MDS initial: 1. Diagnosis of anemia from myelodysplastic syndrome (MDS). 2. Prescribed by or in consultation with a hematologist or oncologist. 3. Age ≥ 18 years. 4. Either (a) current (within 3 months) serum erythropoietin (EPO) ≤ 500 mU/mL, or (b) lower-risk (IPSS low/intermediate-1) disease with symptomatic anemia with del(5q). 5. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or TSAT ≥ 20%. 6. Pretreatment hemoglobin < 10 g/dL. 7. Member meets step therapy: either (a) both (i) member must use Retacrit unless contraindicated/AE/shortage and (ii) if unable to use Retacrit, member must use Epogen unless contraindicated; or (b) request is for treatment in a state with regulations against step therapy in certain oncology settings. Note: For IL HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. This is an off-label indication. Prior authorization may be required for Retacrit or Epogen.

Off-label indication.

Myelofibrosis-Associated Anemia — Initial Therapy (off-label)

Covered when ALL of the following are met:

Myelofibrosis initial: 1. Diagnosis of anemia associated with myelofibrosis. 2. Prescribed by or in consultation with a hematologist or oncologist. 3. Age ≥ 18 years. 4. Current (within 3 months) serum EPO < 500 mU/mL. 5. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or TSAT ≥ 20%. 6. Pretreatment hemoglobin < 10 g/dL. 7. Member meets step therapy: either (a) both (i) member must use Retacrit unless contraindicated/AE/shortage and (ii) if unable to use Retacrit, member must use Epogen unless contraindicated; or (b) request is for treatment in a state with regulations against step therapy in certain oncology settings. Note: For IL HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. This is an off-label indication. Prior authorization may be required for Retacrit or Epogen.

Off-label indication.

CKD — Continued Therapy

Covered when ALL of the following are met:

CKD continued: 1. Member is currently receiving medication via the benefit or previously met initial approval criteria, or continuity of care applies. 2. Member is responding positively to therapy. 3. Member meets both of the following: (a) Member must use Retacrit unless contraindicated, clinically significant adverse effects occur, or Retacrit is unavailable due to shortage; (b) If unable to use Retacrit, member must use Epogen unless contraindicated or clinically significant adverse effects occur. Note: For IL HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. 4. Current hemoglobin ≤ 12 g/dL. 5. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or TSAT ≥ 20%.

Continuation approval durations vary by line of business; prior authorization may be required.

Chemotherapy-Associated Anemia — Continued Therapy

Covered when ALL of the following are met:

Chemo continued: 1. Member is currently receiving medication via the benefit or previously met initial approval criteria, or continuity of care applies. 2. ESA therapy is concurrent with myelosuppressive chemotherapy. 3. If member has received ≥ 8 weeks of ESA therapy, documented response to therapy is present as evidenced by a hemoglobin rise > 1 g/dL and no RBC transfusions required. 4. Current hemoglobin < 10 g/dL. 5. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or TSAT ≥ 20%. 6. Member meets step therapy: either (a) both (i) member must use Retacrit unless contraindicated/AE/shortage and (ii) if unable to use Retacrit, member must use Epogen unless contraindicated; or (b) request is for treatment in a state with regulations against step therapy in certain oncology settings. Note: For IL HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. Continuation is often tied to the duration of the chemotherapy course. Prior authorization may be required for Retacrit or Epogen.

Continuation tied to chemotherapy course duration in many product lines.

MDS — Continued Therapy (off-label)

Covered when ALL of the following are met:

MDS continued: 1. Member is currently receiving medication via the benefit or previously met initial approval criteria, or continuity of care applies. 2. If member has received ≥ 8 weeks of ESA therapy, documented response is present as evidenced by a rise in hemoglobin > 1.5 g/dL or a decrease in RBC transfusion requirement. 3. Current hemoglobin ≤ 12 g/dL. 4. Adequate iron stores: current (within 3 months) serum ferritin ≥ 100 mcg/L or TSAT ≥ 20%. 5. Member meets step therapy: either (a) both (i) member must use Retacrit unless contraindicated/AE/shortage and (ii) if unable to use Retacrit, member must use Epogen unless contraindicated; or (b) request is for treatment in a state with regulations against step therapy in certain oncology settings. Note: For IL HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395. This is an off-label continuation indication. Prior authorization may be required for Retacrit or Epogen.

Off-label continuation criteria; response assessment after ≥ 8 weeks of ESA therapy.

Anemia Associated with Myelodysplastic Syndrome (off-label) — continuation

Covered when ALL of the following are met

MDS continuation criteria: 1. Member is currently receiving medication via the Centene benefit or previously met initial approval criteria, or continuity of care applies. 2. Member must meet both of the following: (i) Member must use Retacrit unless contraindicated, clinically significant adverse effects occur, or Retacrit is unavailable due to shortage; (ii) If unable to use Retacrit, member must use Epogen. (Step therapy bypass for certain states per Appendix D; IL HIM exempt per IL HB 5395). 3. If member has received ≥ 8 weeks of ESA therapy, member must have documented response: either hemoglobin rise > 1.5 g/dL or decreased RBC transfusion requirement. 4. Current hemoglobin ≤ 12 g/dL. 5. Adequate iron stores: ferritin ≥ 100 mcg/L or TSAT ≥ 20% within the last 3 months.see node text

From source chunk 18; off-label continuation.

Myelofibrosis-Associated Anemia (off-label) — continuation

Covered when ALL of the following are met

MF criteria: 1. Member is currently receiving medication via the benefit or previously met initial approval criteria, or continuity of care applies. 2. Member is responding positively to therapy (examples: for transfusion-independent members with baseline hemoglobin < 10 g/dL, a ≥ 2 g/dL hemoglobin increase; or for previously transfusion-dependent members, becoming transfusion-independent). 3. Member must meet both of the following: (i) Member must use Retacrit unless contraindicated, clinically significant adverse effects occur, or Retacrit is unavailable due to shortage; (ii) If unable to use Retacrit, member must use Epogen. (Step therapy bypass per Appendix D; IL HIM exempt per IL HB 5395). 4. Current hemoglobin ≤ 12 g/dL. 5. Adequate iron stores: ferritin ≥ 100 mcg/L or TSAT ≥ 20% within the last 3 months.see node text

Off-label continuation; prior authorization may be required.

Other diagnoses/indications (off-label)

Covered when ALL of the following are met

Other indications redirection: 1. Member meets continuity criteria similar to other sections (currently receiving medication via benefit or previously met initial approval criteria, or continuity of care applies). 2. Member must meet both of the following: (i) Member must use Retacrit unless contraindicated, clinically significant adverse effects occur, or Retacrit is unavailable due to shortage; (ii) If unable to use Retacrit, member must use Epogen. (Step therapy bypass for certain states per Appendix D; IL HIM exempt per IL HB 5395). 3. If the requested use is not listed in the policy or the drug has had a recent label change, follow applicable formulary/non-formulary or off-label policies (CP.CPA.190, HIM.PA.103, CP.PMN.16, CP.CPA.09, HIM.PA.154, CP.PMN.53) as referenced in the policy.see node text

Off-label requests require documentation per off-label use policies referenced.

Aranesp (darbepoetin alfa) is not indicated for several oncology settings per FDA labeling. Specifically, it is not indicated for cancer patients receiving hormonal agents, biologic products, or radiotherapy unless they are also receiving concomitant myelosuppressive chemotherapy. It is not indicated when chemotherapy is expected to be curative, when anemia can be managed by transfusion, or as a substitute for an immediate red blood cell transfusion.

Requests for uses that are non‑FDA approved and not addressed by this policy require submission of sufficient documentation demonstrating efficacy and safety. Such requests will be evaluated against the applicable off‑label use policies (for example, CP.CPA.09, HIM.PA.154, CP.PMN.53) and evidence of coverage documents; absent adequate supporting documentation, coverage is not authorized.

When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for any specific coverage rules that supersede this policy.

FDA labeling explicitly lists settings where Aranesp is not indicated: patients receiving hormonal agents, biologic products, or radiotherapy unless they are also receiving myelosuppressive chemotherapy; patients for whom chemotherapy is expected to be curative; patients whose anemia can be managed by transfusion; and situations requiring immediate correction of anemia where red blood cell transfusion is required.

Off‑label use of Aranesp requires documentation consistent with the plan's off‑label use policies. Providers must supply sufficient clinical evidence of efficacy and safety per the referenced off‑label policies (e.g., CP.CPA.09, HIM.PA.154, CP.PMN.53) and the member's evidence of coverage; without this documentation, coverage for non‑FDA indications is not authorized.

Coding, Lab Thresholds, and Key Clinical Values

HCPCS CodesHCPCS

J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)

Iron studies — ferritin/TSAT requirement

Iron studies thresholdSerum ferritin ≥ 100 mcg/L or serum transferrin saturation (TSAT) ≥ 20% (test within the last 3 months)

Where requiredSpecified as a requirement for CKD, chemotherapy-associated anemia, MDS, myelofibrosis, and continuation criteria

DocumentationProvider must submit current iron studies (within 3 months) with prior authorization or continuation requests

Serum EPO — threshold for some off-label criteria

EPO thresholdSerum erythropoietin (EPO) ≤ 500 mU/mL (current within the last 3 months)

Indications using thresholdRequired for initial MDS criteria (one pathway) and for myelofibrosis initial criteria

Prior Authorization, Step Therapy, and Required Documentation

Prior Authorization

Prior Authorization Required / IL HIM Step Therapy Bypass

Prior authorization is required. For Illinois Humana Integrated Medicaid (IL HIM) requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395 — a step therapy bypass has been added and will be operationalized for IL HIM.

Prior authorization required for Aranesp (darbepoetin alfa).
IL HIM: Step therapy bypass effective 1/1/2026 (IL HB 5395).
Providers should follow operational guidance for IL HIM bypass procedures.

Step Therapy

Step Therapy Requirements and Redirection

Step therapy is required in most lines of business: members must generally trial Retacrit unless contraindicated, experiences clinically significant adverse effects, or Retacrit is unavailable due to shortage. If Retacrit cannot be used, the member must trial Epogen unless contraindicated or clinically significant adverse effects occur. Prior authorization may be required for Retacrit and Epogen. Exceptions include state-specific prohibitions on step therapy (see Appendix C) and the IL HIM bypass (per IL HB 5395).

Line of Therapy Designations

first-line

first-line: Member is receiving myelosuppressive chemotherapy without curative intent and has at least two additional months of planned chemotherapy; age ≥18; pretreatment hemoglobin <10 g/dL; adequate iron stores; prescribed by or in consultation with a hematologist or oncologist.

Line-of-therapy designation: first-line for chemotherapy-associated anemia.

continuation

continuation: ESA therapy must be concurrent with myelosuppressive chemotherapy; documented response after ≥8 weeks (hemoglobin rise >1 g/dL and no RBC transfusions required) where applicable; current hemoglobin thresholds for continuation as specified in section II.

Line-of-therapy designation: continuation.

supportive

Dosing and Covered Regimens

Regimen	Dose / Frequency	Indication	Coverage Status
Starting dose
2.25 mcg/kg SC weekly, or 500 mcg SC every 3 weeks
Anemia due to chemotherapy in patients with cancer — until completion of chemotherapy course
Per dosing section (V. Dosage and Administration)

Regimen	Dose / Frequency	Indication	Coverage Status
NCCN recommended (off-label)
150–300 mcg SC every other week
Anemia associated with myelodysplastic syndrome (MDS) — off-label
Maximum dose listed as 500 mcg every other week (V. Dosage and Administration)

Definitions and Safety Notes

Darbepoetin alfa (Aranesp) — definition

Agent identityDarbepoetin alfa (Aranesp) — an erythropoiesis-stimulating agent (ESA)

Typical FDA usesIndicated for anemia due to chronic kidney disease and anemia from myelosuppressive chemotherapy in non‑myeloid malignancies (see FDA labeling for limits)

Route/formInjection (darbepoetin alfa) — dosing and administration detailed in Appendices/Drug dosing section

Adequate iron stores — policy definition

Adequate iron stores (definition)Serum ferritin ≥ 100 mcg/L or transferrin saturation (TSAT) ≥ 20% within the last 3 months

Required across criteriaStated requirement for initial and continuation approvals in CKD, chemotherapy-associated anemia, MDS, and myelofibrosis

Background on Darbepoetin alfa

Darbepoetin alfa (Aranesp) is an erythropoiesis‑stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (including patients on dialysis and not on dialysis) and for anemia in patients with non‑myeloid malignancies when anemia is caused by concomitant myelosuppressive chemotherapy and the patient has at least a minimum of two additional months of planned chemotherapy. ESAs stimulate red blood cell production by acting on erythroid progenitor cells; clinicians should also note labeled limitations of use, including that Aranesp has not been shown to improve quality of life, fatigue, or patient well‑being, and that it carries risks described in boxed warnings.